Skip to content

Medical emergency? What to do

Avastin Slows Resistant Ovarian Cancer

3-RXPublished June 1, 20123 min read

Key points

  • Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial showed.
  • The objective response rate more than doubled with the addition of the angiogenesis inhibitor, Eric Pujade-Lauraine, MD, of Hopital Hotel-Dieu in Paris, reported here at the American Society for Clinical Oncology meeting.
  • The results constitute a milestone development in the treatment of platinum-resistant ovarian cancer, said Carol Aghajanian, MD, of Memorial Sloan-Kettering Cancer Center in New York City.
  • The findings came from a randomized trial known as AURELIA, which involved patients with ovarian cancer that progressed within 6 months of receiving the last dose of platinum-based chemotherapy.

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial showed.

Median progression-free survival (PFS) increased from 3.4 months with chemotherapy to 6.7 months with chemotherapy and bevacizumab.

The objective response rate more than doubled with the addition of the angiogenesis inhibitor, Eric Pujade-Lauraine, MD, of Hopital Hotel-Dieu in Paris, reported here at the American Society for Clinical Oncology meeting.

"Bevacizumab plus chemotherapy halves the risk of the disease getting worse in platinum-resistant patients, where there is a high unmet need," said Pujade-Lauraine. "Bevacizumab combined with chemotherapy should be considered a new standard option in platinum-resistant ovarian cancer."

The results constitute a milestone development in the treatment of platinum-resistant ovarian cancer, said Carol Aghajanian, MD, of Memorial Sloan-Kettering Cancer Center in New York City.

"These patients, with the usual therapy ... have a low-level response. The drugs work a little bit for a little while," said Aghajanian, who moderated the press briefing. "This is the first trial to show significant improvement in this group of patients."

The findings came from a randomized trial known as AURELIA, which involved patients with ovarian cancer that progressed within 6 months of receiving the last dose of platinum-based chemotherapy.

All patients received one of three standard chemotherapy regimens for platinum-resistant ovarian cancer -- topotecan, paclitaxel, or pegylated liposomal doxorubicin -- as chosen by the treating physicians. The patients were randomized to placebo or to bevacizumab, given concurrently with chemotherapy.

The primary endpoint was PFS, and secondary endpoints included objective response rate, overall survival, safety, and quality of life.

The final analysis included 361 patients. After a median follow-up of 13.5 months, 91% of patients in the chemotherapy-alone arm had progressed compared with 75% in the chemotherapy-bevacizumab arm. The difference translated into a hazard for progression of 0.48 (P<0.001).

"Wow," Pujade-Lauraine said upon displaying survival curves from the study during an ASCO press briefing. "That's exactly what the investigators said when they saw this graph.

"Separation between the curves clearly indicates that adding bevacizumab to chemotherapy is working very well."

Adverse events occurred more often in the bevacizumab arm but were consistent with known effects of the angiogenesis inhibitor and the different chemotherapeutic agents used in the trial.

The most common adverse events in the bevacizumab arm were grade ≥2 hypertension in 20% of patients and proteinuria in 11%. That compared with 7% and 1%, respectively, in the chemotherapy-only arm.

Thromboembolic adverse events occurred in 5% of bevacizumab-treated patients and 4% of patients in the chemotherapy control arm. Pujade-Lauraine reported that 2% of patients in the bevacizumab arm had arterial clot-related events, versus none in the control group.

Pujade-Lauraine disclosed relationships with Roche Diagnostics. Co-investigators disclosed relationships with Roche, AstraZeneca, Boehringer Ingelheim, Janssen-Cilag, Amgen, Novartis, PharmaMar, sanofi, and Merck.

Primary source: American Society of Clinical Oncology
Source reference: Pujade-Lauraine E, et al "AURELIA: A randomized, phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)" ASCO 2012; Abstract LBA5002.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Drug News

Fungus-fighting drug may make mild flu meaner

Mice given a drug commonly used in patients to fight systemic fungal infections more often succumb to what would otherwise be a mild case of the flu. The evidence reported in the Cell Press journal Cell Reports on…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.